Nature Cell Biology, Published online: 22 June 2026; doi:10.1038/s41556-026-01984-y Bae et al. identify MED4 as a regulator of tumour dormancy from a genome-wide CRISPR screen, and show that loss of MED4 alters the enhancer landscape and induces extracellular matrix remodelling to drive metastatic relapse in breast cancer.
Mediator subunit MED4 enforces metastatic dormancy in breast cancer
Filippo G. Giancotti
